De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

BackgroundMetastatic epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) can present de novo or following previous nonmetastatic disease (secondary). Potential differences between these two patient subsets are unclear at present.MethodsWe retrospectively analyzed char...

Full description

Bibliographic Details
Main Authors: Farastuk Bozorgmehr, Daniel Kazdal, Inn Chung, Martina Kirchner, Nikolaus Magios, Mark Kriegsmann, Michael Allgäuer, Laura V. Klotz, Thomas Muley, Rami A. El Shafie, Jürgen R. Fischer, Martin Faehling, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
EGFR+ NSCLC
de novo
secondary
prognosis
comutations
metastatic disease
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.640048/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.640048/full

Similar Items